Nikolay Chekalin
- HHS is purchasing $290M worth of Amgen's (NASDAQ:AMGN) Nplate (romiplostim) for acute radiation sickness due to a radiological or nuclear emergency.
- The treatment was developed by the company with assistance from the Biomedical Advanced Research and Development Authority and National Institute of Allergy and Infectious Diseases.
- Nplate is approved for immune thromocytopenia, a blood disorder characterized by low platelet counts.